DUBLIN, August 25, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Malignant Melanoma Market With Focus on Nevisense System: 2015-2020" report to their offering.
The report titled Global Malignant Melanoma Market With Focus on Nevisense System: 2015-2020 provides an in-depth analysis of the global malignant melanoma market with detailed analysis of the volume of patients and deaths caused due to melanoma. The report also provides the market size of the global melanoma diagnosis and therapeutics market.
The report provides detailed regional analysis of Americas, Europe, Asia, Oceania and Africa for the malignant melanoma market. Regional analysis includes the melanoma diagnosis and therapeutics market, total volume of melanoma patients and deaths caused by melanoma along with the gender segmentation. The report also includes the country analysis of the U.S. and Australia for malignant melanoma market. It provides the analysis of melanoma patient volume along with the deaths caused.
The report also provides detailed information and analysis on the first objective diagnostic support tool, named, Nevisense system manufactured by SciBase company. This section provides the detailed information about the features and clinical benefits of the device along with the technology of the device and its clinical procedures. This also includes the global and regional analysis of the number of devices sold since its invention, i.e. 2014, its installed base and the competitors.
Furthermore, the report assesses key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global melanoma market has also been forecasted for the period 2015-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. The competition in the global melanoma market is stiff and dominated by the big players like Bristol. Further, key players of the melanoma market, Merck and Navidea are also profiled with their financial information and respective business strategies.
Company Coverage
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Navidea Biopharmaceuticals, Inc.
Key Topics Covered:
1. Executive Summary
2. Introduction
2.1 Introduction to Skin Cancer
2.2 Introduction to Malignant Melanoma Skin Cancer
3. Global Market Analysis
3.1 Global Melanoma Diagnosis and Therapeutics Market Analysis
3.2 Global Melanoma Market by New Cases Analysis
3.3 Global Melanoma Market by Deaths Caused Analysis
4. Regional Market Analysis
4.1 Europe Malignant Melanoma Market Analysis
4.2 Americas Malignant Melanoma Market Analysis
The U.S. Melanoma Market by New Cases
The U.S. Melanoma Market by Deaths Caused
4.3 Asia Malignant Melanoma Market Analysis
4.4 Oceania Malignant Melanoma Market Analysis
Australia Melanoma Market by New Cases
Australia Melanoma Market by Deaths Caused
4.5 Africa Malignant Melanoma Market Analysis
5. Melanoma Diagnostic Support Tool: Nevisense
5.1 Introduction to Nevisense
5.2 EIS Technology: Nevisense Action Mechanism
5.3 SciBase Company Profile
5.4 Nevisense Device Installation Base
6. Market Dynamics
6.1 Growth Drivers
6.1.1 Rise in Melanoma Cases
6.1.2 Effective Immunotherapies
6.1.3 Targeted Therapy Drugs
6.2 Challenges
6.2.1 Lack of Awareness among People
6.2.2 High Cost Associated with the Treatment
6.2.3 Challenges in Developing Countries
6.3 Market Trends
6.3.1 Melanoma Vaccines
6.3.2 Diagnostic Tools
6.3.3 Immunotherapy
6.3.4 Melanoma Genetic Research
7. Competitive Landscape
8. Company Profiling
8.1 Bristol-Myers Squibb Company
8.2 Merck & Co., Inc.
8.3 Navidea Biopharmaceuticals, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/tr68sw/global_malignant
Related Topics: Oncology
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
